Brett Williams is a seasoned life science leader with global experience working at Private Equity and Venture capital-funded companies and large multinational public companies. Brett was the CEO at Verogen until the sale to Qiagen and previously was the CEO at Essen BioScience until a successful sale to Sartorius. Before these roles, he was Vice President and General Manager of Thermo Fisher Scientific’s Cellular Analysis business in the LSG group [formally Life Technologies]. The core of the Cellular Analysis business was the Molecular Probes portfolio, where he led the transition from a pure reagents portfolio to a systems business with flow cytometry and imaging instrumentation as well as small benchtop cell counters and fluorimeters.
